TORNTPHARM Q4 FY24 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹2,745 Cr
verified against source
Revenue YoY
10%
reported change
EBITDA
₹883 Cr
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Torrent Pharma delivered a solid Q4 FY24 with consolidated revenue of INR 2,745 crore (+10% YoY) and EBITDA of INR 883 crore (+21% YoY), translating to 32% EBITDA margins. India business grew 10% to INR 1,380 crore, outperforming IPM (9%) with chronic therapies accelerating at 14%. Brazil emerged as the largest affiliate outside India with INR 1,126 crore revenue, growing 14% and approaching BRL 1 billion milestone. Germany delivered EUR 120 million at 8% growth with meaningful tender wins from Q2 FY25. US business at $32 million declined 7% but management expects turnabout in FY25 with ~8 approvals expected. Gross debt stands at INR 3,900 crore (0.87x leverage), with INR 1,300-1,500 crore repayment planned for FY25. Management guided 50-100bps margin expansion for FY25. Key risks include US pricing pressure from Dapsone competition, Red Sea-related freight cost inflation (+INR 10 crore in Q4), and moderating Brazil pricing (4% vs 10% market growth). Management indicated no M&A proposals currently in pipeline despite enabling resolution for INR 5,000 crore equity issuance.
Colored figures show movement against the previous available record.
Guidance to track
- With IPM growth expected at ~9%, management expects India business to grow at 11-12% in FY25, driven by chronic therapy expansion, new launches, and field force productivity improvements.
- Management expects Brazil to continue its strong momentum with ~15% constant currency growth, supported by new launches, volume growth, and price increases of ~4.5% announced in April.
- With tender wins flowing from Q2 FY25 and 10-15 product launches planned, Germany is expected to maintain high single-digit growth trajectory.
- Margin improvement expected from price increases across branded generic segments, operating leverage in Germany and Brazil, and positive US contribution. Excludes planned incremental consumer health investments.
Risks flagged
- New competitors for Dapsone (Torrent's leading US product) continue to impact revenues. Management expects 8 approvals in FY25 but competitive intensity remains elevated.
- Price growth in Brazil is ~4% (vs ~10% market growth). While volume and new products compensate, any further pricing pressure could impact growth trajectory toward BRL 1 billion target.
- Freight expenses increased by ~INR 10 crore in Q4 due to Red Sea disruptions. Extended transit times and cost pressures could persist and compress margins if not managed.
- Analyst raised concern about trade generics impacting chronic volumes in IPM. Management acknowledged difficulty gaining traction in chronic space but noted competitive intensity increasing across segments.
Key quotes
- US should start contributing positively to the overall growth in FY 2025
- We believe we should be well placed to grow a couple of percent, maybe 2-3% higher than IPM. In terms of growth breakup, we registered a growth of 15% in the AIS three data in Q4. The breakup of that is 3% volume, 8% price and 4% new products.
- Over the medium term, we would anticipate a business of, say, $250 million-$300 million, if, you know, as new product launches come in.
Research modules